The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Alongside the CFO , I also question the Chairman’s judgement.
Whilst Dr Coughlin has impressive scientific and clinical experience, it’s her business skills that will now come under scrutiny. A CEO at CytoImmune which lasted less than 2 years isn’t a ringing endorsement. Would have preferred she retained her clinical role but maybe few external candidates were that attracted, so rather than wait EF decided upon a hasty solution with AS probably setting the deadline. Hence now acknowledges more weight is still needed .
I’m under the impression that Ed Milliband’s rhetoric is increasing becoming more extreme, as he see’s the continuing attacks on his Net Zero fantasy land hitting home. This will hopefully just help to widen the distance between himself and those with more moderate views, the likes of Rachel Reeves would seem to hold. At least Labours manifesto will show where the real power lies in this particular arena, and I’d be surprised if it’s not wearing a skirt !
Remember Nat R. bought 60,000 shares at over £4 a couple of years ago, so even then he saw value, we’ve moved up a few gears since so every chance you’ll get your wish !
“Everything Alistar said can now be disregarded” ….you mean this as well in his last dying breath ..“ Avacta has been able to leverage this excellent progress in the clinic to progress conversations with potential commercial partners “. I think many are now left wondering who to believe, it certainly ain’t the Chairman !
Disappointed AS has been ousted, CC turns the language down and DX to go. Just hope CC ‘s business skills match her scientific ones. Meanwhile the CFO and Chairman ( don’t worry about funding ) escape….hmm, not impressed. Shall now review my investment here.
Good to see a little momentum leading into YE Results, but still some way to go before a review of holding is required. We first need to hit Jefferies target !
Interesting article in the Times today, about Zandy Forbes, the eccentric CEO of MeiraGTx, another promising UK biotech. Her comments resonate here;
“Would she have floated on the LSE, if she had her time again? Absolutely not, she says. Small biotechs are risky, “money-burning endeavours,” she says. Meira, for example, invests in developing new medicines, but does not sell any treatments to patients yet.
While US pension funds and hedge funds have spent two decades gaining expertise in how to evaluate and invest in such drug developers, UK investors are simply not prepared to fund those risks.”
And as we’ve found out !
PL. Many companies get away with Placings at much thinner discounts to the prevailing SP, why because their perceived risk factors are much lower, ours clearly aren’t in the eyes of those approached for funding support who will have studied all availability Data.. Professional investors are merely cold and calculated, unlike most retail investors who buy and suddenly fall in love with the stock, often losing substantial capital thus would be more appropriate to describe them as ‘clueless ‘. Witness the level of passion on this BB when finding AS has strung them along yet again, or heaven forbid someone has gone Short !